M&A funding through the issuance of stock acquisition rights and repayment of borrowings
First written in FY2018-Q3. 2 of 4 entries say "Advanced", first in FY2018. Latest entry: FY2019.
Medical System Network moved to the "Worse" side of this theme in 2019.
0 other companies' latest entry also says "Softened".
- FY2019SoftenedAnnual report
「Based on a resolution of the Board of Directors meeting held on 8 May 2019, all outstanding stock acquisition rights were acquired and cancelled as of 27 May 2019.」
By the end of the fiscal year, 753 fourth-series stock acquisition rights had been exercised, raising ¥387 million, and all outstanding rights were acquired and cancelled after the filing. The planned financing facility ended without being fully drawn. - FY2019-Q1AdvancedAnnual report
「Number of stock acquisition rights with an exercise-price adjustment clause, including bonds with stock acquisition rights, exercised during the current quarterly accounting period (units): 120」
During the current quarter, 120 fourth-series stock acquisition rights were exercised, 120,000 shares were delivered and ¥60 million was raised. Cumulative exercises reached 753 units and cumulative proceeds reached ¥387 million, with the financing continuing to progress. - FY2018AdvancedAnnual report
「Number of stock acquisition rights with an exercise-price adjustment clause, including bonds with stock acquisition rights, exercised during the period (units): 633」
A total of 633 fourth-series stock acquisition rights were exercised, 633,000 shares were delivered and ¥326 million was raised. The disclosure does not establish the specific amount actually allocated to M&A funding or repayment of borrowings. - FY2018-Q3First statedAnnual report
「Use of funds: ① M&A funding to strengthen services and expand the scale of the pharmaceutical network business; ② repayment of borrowings to strengthen the financial base」
The company announced a plan to raise estimated net proceeds of ¥3,287.865 million through the issuance of the fourth series of stock acquisition rights with an exercise-price adjustment clause on 9 January 2018. The exercise period ran from 10 January 2018 to 9 January 2020, and the proceeds were to be used for M&A in the network business and repayment of borrowings.